Posted by Michael Wonder on 12 Jul 2018
NICE says no to Darzalex
12 July 2018 - NICE says no to myeloma ‘game changer’.
England’s cost effectiveness watchdog NICE has issued draft guidance not recommending Janssen's Darzalex (daratumumab) for second line use in multiple myeloma in combination with existing treatments.
Among a wave of new myeloma treatments, Darzalex is seen as one of the most promising, with clinicians describing it as a ‘game changer’ in terms of prolonging lives of patients.
